Author: Sato Akinori Asano Takako Ito Keiichi Asano Tomohiko
Publisher: Spandidos Publications
ISSN: 1019-6439
Source: International Journal of Oncology, Vol.41, Iss.1, 2012-07, pp. : 46-52
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Our previous study showed that the combination of a histone deacetylase (HDAC) inhibitor and an HIV protease inhibitor is effective against renal cancer cells. Because HDAC inhibition disrupts the chaperon function of heat shock protein (HSP) 90, we hypothesized that the combination of 17-allylamino-17-demethoxygeldanamycin (17-AAG), an inhibitor of HSP90, and the HIV protease inhibitor ritonavir would also act against renal cancer. The combination of 17-AAG and ritonavir induced apoptosis and inhibited the proliferation of renal cancer cells effectively. It also suppressed the expression of cyclin-dependent kinase 4 and cyclin D1, leading to the accumulation of the cells in the sub-G1 fraction. The expression of HSPs 27, 70 and 90 was increased by 17-AAG alone but reduced by 17-AAG combined with ritonavir. The combination decreased the expression of heat shock factor-1 (HSF-1), an HSP transcription factor, and this might be one of the mechanisms of the effect of the combination. We have also found that silencing of HSF-1 by siRNA inhibited the proliferation of renal cancer cells and that in surgically resected specimens the levels of HSF-1 expression in renal cancer tissue are higher than those in normal parenchyma. This is the first study showing the beneficial effect of combining 17-AAG and ritonavir and our data suggest that HSF-1 may be a novel therapeutic target in the treatment of renal cancer.
Related content
By Banerji Udai Sain Nivedita Sharp Swee Valenti Melanie Asad Yasmin Ruddle Ruth Raynaud Florence Walton Michael Eccles Suzanne Judson Ian Jackman Ann Workman Paul
Cancer Chemotherapy and Pharmacology, Vol. 62, Iss. 5, 2008-10 ,pp. :
By Cui Yuehong Wu Weizhong Zhou Yuhong Xie Qian Liu Tianshu Jin Jianjun Liu Kangda
Future Oncology, Vol. 9, Iss. 3, 2013-03 ,pp. :
By Egorin Merrill J. Zuhowski Eleanor G. Rosen D. Marc Sentz Dorothy L. Covey Joseph M. Eiseman Julie L.
Cancer Chemotherapy and Pharmacology, Vol. 47, Iss. 4, 2001-04 ,pp. :
By Gartner Elaina Silverman Paula Simon Michael Flaherty Lawrence Abrams Judith Ivy Percy LoRusso Patricia
Breast Cancer Research and Treatment, Vol. 131, Iss. 3, 2012-02 ,pp. :
Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 15, Iss. 10, 2015-12 ,pp. :